Our pipeline

We have an exciting and balanced pipeline underpinned by great science.

Latest quarterly updates

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

132

projects in our pipeline

12

new molecular entities in our late-stage pipeline


Phase III/Reg.* refers to assets that are in Phase III or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Filter By:

Oncology (as at 2 February 2017)

Phase 1

Phase 1

  • AZD0156 solid tumours
  • AZD2811 solid tumours
  • AZD4635 solid tumours
  • AZD6738 solid tumours
  • AZD8186 solid tumours
  • AZD9150 haematological malignancies
  • AZD9496 ER+ breast cancer
  • Lynparza + AZD1775 solid tumours
  • MEDI-565 solid tumours
  • MEDI0562 solid tumours
  • MEDI0680 solid tumours
  • MEDI1873 solid tumours
  • MEDI4276 solid tumours
  • MEDI9197 solid tumours
  • MEDI9447 solid tumours
  • durvalumab + AZD1775 solid tumours
  • durvalumab + Iressa NSCLC
  • durvalumab + MEDI0562 solid tumours
  • durvalumab + MEDI9447 solid tumours
  • durvalumab + dabrafenib + trametinib melanoma
  • durvalumab + monalizumab solid tumours
  • durvalumab + selumetinib solid tumours
  • durvalumab + tremelimumab solid tumours
  • durvalumab or durvalumab + (tremelimumab or AZD9150) diffuse large B-cell lymphoma
  • tremelimumab + MEDI0562 solid tumours

Phase 2

Phase 2

  • AZD1775 solid tumours
  • AZD1775 + chemotherapy ovarian cancer
  • AZD4547 solid tumours
  • AZD5363 breast cancer
  • Lynparza + AZD6738 gastric cancer
  • MEDI-573 metastatic breast cancer
  • Tagrisso (AZD9291) + (durvalumab or selumetinib or savolitinib) TATTON advanced EGFRm NSCLC
  • Tagrisso BLOOM CNS metastases in advanced EGFRm NSCLC
  • durvalumab solid tumours
  • durvalumab + AZD5069 durvalumab + AZD9150 HNSCC
  • durvalumab + MEDI0680 solid tumours
  • durvalumab + tremelimumab Hepatocellular carcinoma (liver cancer)
  • durvalumab + tremelimumab gastric cancer
  • savolitinib/ volitinib papillary renal cell carcinoma
  • vistusertib solid tumours

Phase 3

Phase 3

  • Tagrisso (AZD9291) AURA, AURA 2, (AURA17 CN) ≥2nd-line advanced EGFRm T790M NSCLC
  • Tagrisso AURA3 ≥2nd-line advanced EGFRm T790M NSCLC
  • acalabrutinib B-cell malignancy
  • acalabrutinib 1st line CLL
  • acalabrutinib r/r CLL, high risk
  • durvalumab ≥2nd-line advanced bladder cancer
  • durvalumab PACIFIC stage III NSCLC
  • durvalumab + tremelimumab ARCTIC 3rd-line NSCLC
  • durvalumab + tremelimumab DANUBE 1st-line bladder
  • durvalumab + tremelimumab EAGLE 2nd-line SCCHN
  • durvalumab + tremelimumab KESTREL 1st-line SCCHN
  • durvalumab + tremelimumab MYSTIC 1st-line NSCLC
  • durvalumab + tremelimumab NEPTUNE 1st-line NSCLC
  • moxetumomab pasudotox PLAIT hairy cell leukaemia
  • selumetinib ASTRA differentiated thyroid cancer

LCM Projects

LCM Projects

  • Faslodex FALCON 1st-line hormone receptor +ve advanced breast cancer
  • Lynparza prostate cancer
  • Lynparza (olaparib) SOLO-1 1st-line BRCAm ovarian cancer
  • Lynparza (olaparib) SOLO-2 2nd-line or greater BRCAm PSR ovarian cancer, maintenance monotherapy
  • Lynparza (olaparib) SOLO-3 gBRCA PSR ovarian cancer
  • Lynparza OlympiA gBRCA adjuvant breast cancer
  • Lynparza OlympiAD gBRCA metastatic breast cancer
  • Lynparza POLO pancreatic cancer
  • Tagrisso (AZD9291) ADAURA adjuvant EGFRm NSCLC
  • Tagrisso (AZD9291) FLAURA 1st-line advanced EGFRm NSCLC

Cardiovascular and Metabolic Diseases (as at 2 February 2017)

Phase 1

Phase 1

  • AZD4831 HFpEF
  • AZD5718 CAD
  • AZD8601 cardiovascular
  • MEDI8111 trauma/bleeding

Phase 2

Phase 2

  • AZD4076 non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH)
  • MEDI0382 diabetes/obesity
  • MEDI4166 diabetes/cardiovascular
  • MEDI6012 ACS

Phase 3

Phase 3

  • Brilinta/Brilique arterial thrombosis
  • Epanova severe hypertriglyceridaemia
  • Farxiga/Forxiga type-2 diabetes
  • ZS-9 (sodium-zirconium cyclosilicate) hyperkalaemia
  • roxadustat OLYMPUS ROCKIES anaemia in CKD/ESRD

LCM Projects

LCM Projects

  • Brilinta/Brilique PEGASUS- TIMI 54 outcomes study in patients with prior myocardial infarction
  • Brilinta/Brilique HESTIA prevention of vaso-occlusive crises in paediatric patients with sickle cell disease
  • Brilinta/Brilique THEMIS outcomes study in patients with type-2 diabetes and CAD, but without a previous history of MI or stroke
  • Bydureon EXSCEL type-2 diabetes outcomes study
  • Bydureon weekly suspension type-2 diabetes
  • Epanova STRENGTH outcomes study in statin-treated patients at high CV risk, with persistent hypertriglyceridemia plus low HDL-cholesterol
  • Farxiga/Forxiga type-1 diabetes
  • Farxiga/Forxiga DECLARE- TIMI 58 type-2 diabetes outcomes study
  • Kombiglyze XR/Komboglyze type-2 diabetes
  • Onglyza SAVOR-TIMI 53 type-2 diabetes outcomes study
  • Qtern (saxagliptin/dapagliflozin FDC) type-2 diabetes
  • Xigduo XR/Xigduo type-2 diabetes

Respiratory (as at 2 February 2017)

Phase 1

Phase 1

  • AZD0284 psoriasis
  • AZD5634 cystic fibrosis
  • AZD7594 + abediterol asthma/COPD
  • AZD7986 COPD
  • AZD9567 rheumatoid arthritis
  • MEDI9314 atopic dermatitis

Phase 2

Phase 2

  • AZD1419 asthma
  • AZD7594 asthma/COPD
  • AZD8871 COPD
  • AZD9412 asthma/COPD
  • PT010 asthma
  • abediterol asthma/COPD
  • tezepelumab asthma/atopic dermatitis

Phase 3

Phase 3

  • Bevespi Aerosphere (PT003) GFF PINNACLE COPD
  • PT010 COPD
  • benralizumab CALIMA SIROCCO ZONDA BISE BORA GREGALE severe asthma
  • benralizumab TERRANOVA GALATHEA COPD
  • tralokinumab STRATOS 1,2 TROPOS MESOS severe asthma

LCM Projects

LCM Projects

  • Duaklir Genuair COPD
  • Symbicort breath actuated Inhaler asthma/COPD
  • Symbicort SYGMA as-needed use in mild asthma

Other (as at 2 February 2017)

Phase 1

Phase 1

  • MEDI0700 systemic lupus erythematosus
  • MEDI1814 Alzheimer’s disease
  • MEDI4920 primary Sjögren’s syndrome
  • MEDI7352 osteoarthritis pain
  • MEDI7734 myositis
  • anifrolumab systemic lupus erythematosus (subcutaneous)

Phase 2

Phase 2

  • AZD3241 multiple system atrophy
  • MEDI3902 prevention of nosocomial pseudomonas pneumonia
  • MEDI4893 hospital-acquired pneumonia/serious S. aureus infection
  • MEDI5872 primary Sjögren’s syndrome
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis
  • anifrolumab lupus nephritis
  • inebilizumab neuromyelitis optica
  • mavrilimumab rheumatoid arthritis
  • verinurad chronic treatment of hyperuricemia in patients with gout

Phase 3

Phase 3

  • AZD3293 AMARANTH DAYBREAK-ALZ Early Alzheimer's disease
  • anifrolumab TULIP systemic lupus erythematosus

LCM Projects

LCM Projects

  • Nexium stress ulcer prophylaxis
  • Nexium paediatrics
  • linaclotide irritable bowel syndrome with constipation (IBS-C)

Terminations

  • durvalumab HAWK solid tumours
  • durvalumab + tremelimumab CONDOR 2nd-line SCCHN (PD-L1 negative)
  • durvalumab + tremelimumab ALPS metastatic pancreatic ductal carcinoma
  • Zinforo pneumonia/skin infections
  • Zavicefta (CAZ AVI) serious infections, complicated intraabdominal infection, complicated urinary tract infection
  • Zavicefta (CAZ AVI) hospital-acquired pneumonia/ ventilator-associated pneumonia
  • durvalumab solid tumours
  • Tagrisso LM
  • MEDI2070 Crohn’s disease
  • CXL MRSA
  • MEDI7510 prevention of RSV disease in older adults
  • ATM AVI targeted serious bacterial infections
  • AZD8108 suicidal ideation